📊 CABA Key Takeaways
Is Cabaletta Bio, Inc. (CABA) a Good Investment?
Cabaletta Bio is a pre-revenue biotech company with severe cash burn and negative profitability metrics, losing $125.9M annually with an operating cash outflow of $95.7M. While the company maintains adequate liquidity with $60.2M in cash and a 3.60x current ratio, the burn rate at current levels suggests less than 18 months of runway without additional funding or operational changes. The absence of revenue combined with deteriorating unit economics (negative ROE of -90.3% and ROA of -66.4%) indicates the company remains in early clinical/development stages with substantial execution risk.
Cabaletta Bio remains a pre-revenue biotech with deeply negative operating income, net income, and free cash flow, so the fundamentals are still driven by capital consumption rather than self-sustaining business performance. The balance sheet is helped by solid near-term liquidity and no long-term debt, but cash of $60.21M against operating cash burn of $95.74M suggests meaningful financing risk unless spending falls materially or clinical progress supports new funding on acceptable terms.
Why Buy Cabaletta Bio, Inc. Stock? CABA Key Strengths
- Adequate near-term liquidity with $60.2M cash and 3.60x current ratio providing runway for operations
- Conservative balance sheet with zero long-term debt and low leverage (0.00x debt/equity ratio)
- Significant shareholder equity base of $139.5M suggesting prior capital raises and investor backing
- Strong liquidity ratios at 3.60x current and quick ratio support near-term operations
- No long-term debt and 0.00x debt/equity reduce balance-sheet leverage risk
- Positive equity base of $139.47M provides some financial cushion relative to liabilities
CABA Stock Risks: Cabaletta Bio, Inc. Investment Risks
- Pre-revenue company with $125.9M net losses and $95.7M annual operating cash burn indicating unsustainable economics without clinical/commercial success
- Less than 18 months of cash runway at current burn rate, necessitating additional capital raise or dramatic operational improvements
- Early stage biotech with no revenue generation and uncertain path to profitability; high probability of total capital loss if pipeline assets fail in development
- No revenue base means business quality depends entirely on pipeline execution rather than commercial fundamentals
- Large operating loss of $129.63M and negative free cash flow of $96.76M indicate heavy ongoing cash burn
- Cash and equivalents of $60.21M appear limited relative to annual operating cash outflow, raising dilution or capital-raise risk
Key Metrics to Watch
- Operating cash burn rate and runway to profitability or next funding milestone
- Clinical trial progression and regulatory pathway status for lead candidates
- Quarterly cash position changes and any announcement of financing activities or partnerships
- Quarterly operating cash burn relative to cash and equivalents
- Pipeline-driven revenue emergence or major reduction in operating losses
Cabaletta Bio, Inc. (CABA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.60x current ratio provides a solid financial cushion.
CABA Profit Margin, ROE & Profitability Analysis
CABA vs Healthcare Sector: How Cabaletta Bio, Inc. Compares
How Cabaletta Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cabaletta Bio, Inc. Stock Overvalued? CABA Valuation Analysis 2026
Based on fundamental analysis, Cabaletta Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cabaletta Bio, Inc. Balance Sheet: CABA Debt, Cash & Liquidity
CABA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cabaletta Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.34 indicates the company is currently unprofitable.
CABA Revenue Growth, EPS Growth & YoY Performance
Cabaletta Bio, Inc. Dividends, Buybacks & Capital Allocation
CABA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cabaletta Bio, Inc. (CIK: 0001759138)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CABA
What is the AI rating for CABA?
Cabaletta Bio, Inc. (CABA) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CABA's key strengths?
Claude: Adequate near-term liquidity with $60.2M cash and 3.60x current ratio providing runway for operations. Conservative balance sheet with zero long-term debt and low leverage (0.00x debt/equity ratio). ChatGPT: Strong liquidity ratios at 3.60x current and quick ratio support near-term operations. No long-term debt and 0.00x debt/equity reduce balance-sheet leverage risk.
What are the risks of investing in CABA?
Claude: Pre-revenue company with $125.9M net losses and $95.7M annual operating cash burn indicating unsustainable economics without clinical/commercial success. Less than 18 months of cash runway at current burn rate, necessitating additional capital raise or dramatic operational improvements. ChatGPT: No revenue base means business quality depends entirely on pipeline execution rather than commercial fundamentals. Large operating loss of $129.63M and negative free cash flow of $96.76M indicate heavy ongoing cash burn.
What is CABA's revenue and growth?
Cabaletta Bio, Inc. reported revenue of N/A.
Does CABA pay dividends?
Cabaletta Bio, Inc. does not currently pay dividends.
Where can I find CABA SEC filings?
Official SEC filings for Cabaletta Bio, Inc. (CIK: 0001759138) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CABA's EPS?
Cabaletta Bio, Inc. has a diluted EPS of $-1.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CABA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cabaletta Bio, Inc. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CABA stock overvalued or undervalued?
Valuation metrics for CABA: ROE of -90.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CABA stock in 2026?
Our dual AI analysis gives Cabaletta Bio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CABA's free cash flow?
Cabaletta Bio, Inc.'s operating cash flow is $-95.7M, with capital expenditures of $1.0M.
How does CABA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -90.3% (avg: 15%), current ratio 3.60 (avg: 2).